ALKBH5 and cancer: Although several inhibitors like IOX3 17, MV1035 18, ALK-04 19 have been developed to target ALKBH5, none have received clinical approval for cancer treatment, likely due to issues with target specificity, therapeutic effectiveness, safety, and pharmacokinetics.